Artivion (NYSE:AORT) Trading Down 4.2%

Artivion, Inc. (NYSE:AORTGet Free Report)’s share price dropped 4.2% on Friday . The stock traded as low as $24.44 and last traded at $24.76. Approximately 88,383 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 216,365 shares. The stock had previously closed at $25.85.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AORT. Needham & Company LLC boosted their price objective on shares of Artivion from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Stifel Nicolaus boosted their price target on Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Finally, Lake Street Capital raised their price objective on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd.

View Our Latest Analysis on Artivion

Artivion Price Performance

The company has a quick ratio of 4.26, a current ratio of 6.04 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -105.29 and a beta of 1.75. The business’s 50 day simple moving average is $23.42 and its 200-day simple moving average is $20.59.

Artivion (NYSE:AORTGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. The company had revenue of $97.43 million during the quarter, compared to the consensus estimate of $92.30 million. Artivion had a negative net margin of 2.61% and a positive return on equity of 3.64%. On average, research analysts forecast that Artivion, Inc. will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Artivion

Several hedge funds and other institutional investors have recently modified their holdings of AORT. Wasatch Advisors LP raised its stake in Artivion by 108.8% during the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock worth $22,928,000 after acquiring an additional 564,549 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Artivion by 5.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,686,502 shares of the company’s stock valued at $30,156,000 after purchasing an additional 80,214 shares during the last quarter. GSA Capital Partners LLP increased its position in Artivion by 187.5% during the 3rd quarter. GSA Capital Partners LLP now owns 82,449 shares of the company’s stock worth $1,250,000 after purchasing an additional 53,773 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in Artivion in the 4th quarter valued at approximately $916,000. Finally, First Eagle Investment Management LLC boosted its position in Artivion by 8.1% in the first quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock valued at $12,066,000 after buying an additional 42,705 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Recommended Stories

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.